About Gliknik - Board of Directors
David S. Block - Chairman
Skip Klein - Non-executive Director
For 10 years Mr. Klein was a portfolio manager and securities analyst at T. Rowe Price Associates, Inc. and The Kaufmann Fund, Inc. before serving from June 1999 on as Vice President, Strategy, for Medical Manager Corporation, a leading developer of physician office management information systems, until it merged with WebMD Corporation in September 2000. Mr. Klein currently serves on the Board of Directors of the following publicly traded biopharmaceutical companies: BioMarin Pharmaceutical Inc., Isis Pharmaceuticals, Inc., OSI Pharmaceuticals, Inc., PDL BioPharma, and Savient Pharmaceuticals, Inc. Mr. Klein has also served as a Venture Partner of Red Abbey Venture Partners, LP, a life sciences private equity fund and as a Venture Partner of MPM Capital, a healthcare venture capital firm. Mr. Klein received a B.A. in economics from Yale University and an M.B.A. from the Stanford Graduate School of Business.
Raymond Schinazi, Ph.D., D.Sc. (Hon.) - Non-executive Director
Dr. Schinazi is the founder or co-founder of several biotechnology companies that progressed from startup through IPO, including Pharmasset Inc., Triangle Pharmaceuticals (acquired by Gilead Sciences in 2003), and Idenix Pharmaceuticals (54% acquired by Novartis in 2003). Dr. Schinazi founded RFS Pharma LLC in September 2004. Dr. Schinazi is best known for his pioneering work on d4T (stavudine, Zerit®), 3TC (lamivudine, Epivir®), and FTC (emtricitabine, Emtriva&®), drugs that progressed through NDA and are now approved by the FDA, as well as for his work on D-D4FC (Reverset®), racemic FTC (Racivir®), and DAPD (amdoxovir), which are at various stages of clinical development. He is Professor of Pediatrics and Chemistry at Emory University and Georgia State Unversity, respectively. He is also a Senior Research Career Scientist at the Atlanta Department of Veterans Affairs. He is the virology/pharmacology core co-director for the Emory Center for AIDS Research (CFAR). He has published over 400 peer-reviewed papers and seven books, holds more than 70 US patents, and is on the editorial board of several journals.
Sol Langermann Ph.D. - Board Observer
Dr. Langermann is head of research and development at Amplimmune, Inc. Dr. Langermann spent 12 years at MedImmune, Inc. where he held a number of positions including Senior Director of the Department of Cell Biology. Subsequently he joined PharmAthene, Inc. where he headed up the Research and Development efforts. He received his Ph.D. from Tufts University and completed his postdoctoral fellowship and a Masters degree at Harvard University.